Skip to main content
. Author manuscript; available in PMC: 2019 May 28.
Published in final edited form as: Leukemia. 2018 Feb 22;32(9):1932–1947. doi: 10.1038/s41375-018-0062-8

Fig. 3.

Fig. 3

Upregulation of CD80, CD86, HLA-ABC and HLA-DP/DQ/DR on tumor and dendritic cells and induction of T cell proliferation with ACY241 treatment. ACY241 treatment increased expression of CD80/CD86 (Fig. 3a) and HLA-A2, HLA-ABC, and HLA-DP/DQ/DR (Fig. 3b) on myeloma U266, breast cancer MDA-MB231, and/or colon cancer SW480 cells in a dose-dependent manner (p < 0.05). ACY241 (1 (μM)-treated dendritic cells induced a high level of proliferation of CD3+ T cells, including both CD4+ and CD8+ cells, in mixed lymphocytes reactions (Fig. 3c)